CA
NZ
UK
AU
IND
US
Penny stock Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biotechnology company developing treatments for fibrotic and inflammatory diseases, with its lead candidate, nebokitug, being developed for primary sclerosing cholangitis, a serious and rare liver disease with limited treatment options. Shares traded at $2.84 in today's …
STERIS (NYSE:STE) is a leading provider of infection-prevention and sterilization products and services, serving healthcare, pharmaceutical, and other customers with sterilization services, surgical and infection-prevention products, andCapitalequipment. Shares closed at $226.83 at last closing, down 1.53%.
Tempus AI (NASDAQ:TEM) is a health-technology company that applies artificial intelligence andData Analyticsto precision medicine, generating and analyzing molecular and clinical data, particularly in oncology. Shares closed at $64.66 at last closing, up 4.39%.
Penny stock MaxCyte (NASDAQ:MXCT) is a life-sciences company that provides cell-engineering technology, primarily its electroporation-based platform used to deliver molecules into cells, important in the development of cell therapies and gene-edited therapies. Shares closed at $1.26 at last closing, down 0.79%.
Medicus Pharma Ltd. (NASDAQ: MDCX) shares closed down 34% at $0.17 following a worldwide licensing agreement with Pfizer for the early-stage CD228V ADC asset PF-08046031.
Hutchmed (China) Limited (NASDAQ: HCM) shares closed up 17% at $14.11 after entering an exclusive ex-China development and commercialization license with GSK for HMPL-A830, receiving $110 million upfront and up to $1.3 billion in total milestones plus royalties.
Aptevo Therapeutics, Inc. (NASDAQ: APVO) shares closed down 34% at $1.71 despite reporting interim RAINIER data in frontline TP53-mutated AML showing 93% clinical benefit and 79% CR/CRi among 14 evaluable patients treated with mipletamig plus venetoclax and azacitidine.
BioRestorative Therapies, Inc. (NASDAQ: BRTX) shares closed down 29% at $0.14 as the company is set to execute a 1-for-20 reverse stock split on September 7, 2026.
bioAffinity Technologies, Inc. (NASDAQ: BIAF) shares closed up 31% at $12.78 as the company advances its CyPath Lung platform for post-therapeutic lung cancer monitoring.
Biotech news over September 3 and 4, 2026 spanned a wide range of developments, from a new FDA approval and a major licensing deal to a clinical trial miss and several financing and corporate updates across more than a dozen companies.
Please wait processing your request...